<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296269</url>
  </required_header>
  <id_info>
    <org_study_id>OXTandAVP-HMO-CTIL</org_study_id>
    <nct_id>NCT01296269</nct_id>
  </id_info>
  <brief_title>Effects of Intranasal Oxytocin and Vasopressin on Social Behavior</brief_title>
  <official_title>Effects of Intranasal Oxytocin and Vasopressin on Social Behavior in Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebrew University of Jerusalem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the role of a one-time intranasal administration
      of the oxytocin, vasopressin, or placebo on prosocial decision making such as cooperation and
      altruism in a healthy population of student controls.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>allocations of monetary units</measure>
    <time_frame>approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo</time_frame>
    <description>Participants will make decisions regarding the allocation of monetary units between themselves and other participants. We will measure the quantity of monetary units kept for themselves vs. given to other participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mood as measured via the visual analog scale</measure>
    <time_frame>approximately one hour and fifteen minutes after administration of oxytocin, vasopressin or placebo</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Vasopressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vasopressin condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxytocin condition (syntocinon)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>one-time intranasal administration, 24 International Units, 5 puffs for each nostril</description>
    <arm_group_label>oxytocin</arm_group_label>
    <other_name>syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arginine Vasopressin</intervention_name>
    <description>one-time intranasal administration, 20 International Units, 5 puffs in each nostril</description>
    <arm_group_label>Vasopressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy controls

        Exclusion Criteria:

          -  Past or present psychiatric, neurological, endocrinological or severe chronic medical
             illness.

          -  Use of medications or drugs that would interfere with study results. This includes
             steroids, medications for psychiatric symptoms like anxiety or depression, stimulants,
             and medications for high blood pressure. Participants will be asked to tell the
             investigators of any medications or drugs that they are taking. The investigators will
             consider the drug interactions with oxytocin and vasopressin prior to study, and
             participants will not be able to participate in the study if the drug interactions
             could be dangerous.

          -  history of drug or alcohol addiction

          -  Pregnancy or Nursing Status: Because of the risk to an unborn fetus or infant, women
             who are pregnant or nursing are excluded from this protocol. All females will have a
             pregnancy test performed no more than 24 hours before each drug administration and
             will not be able to participate if the pregnancy test is positive.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mankuta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah University Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Mankuta, MD</last_name>
    <phone>972-2-6776484</phone>
    <email>mankutad@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salomon Israel, MA</last_name>
    <phone>972-524789754</phone>
    <email>salomon.israel@mail.huji.ac.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah University Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Mankuta, MD</last_name>
      <phone>972-2-6776484</phone>
      <email>mankutad@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Salomon Israel, MA</last_name>
      <phone>972-52-4789754</phone>
      <email>salomon.israel@mail.huji.ac.il</email>
    </contact_backup>
    <investigator>
      <last_name>David Mankuta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>David Mankuta MD</name_title>
    <organization>Hadassah Ein-Kerem - obstetrics and gynecology</organization>
  </responsible_party>
  <keyword>social cognition</keyword>
  <keyword>oxytocin</keyword>
  <keyword>vasopressin</keyword>
  <keyword>decision making</keyword>
  <keyword>social decision making</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

